Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel

BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration‐resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased prostate‐specific antigen (PSA) levels. The goal of this post hoc analysis wa...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer
Main Authors: Armstrong, Andrew J., Saad, Fred, Phung, De, Dmuchowski, Carl, Shore, Neal D., Fizazi, Karim, Hirmand, Mohammad, Forer, David, Scher, Howard I., Bono, Johann De
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2017
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5484320/
https://ncbi.nlm.nih.gov/pubmed/28171710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30587
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker